MS and Demyelinating Disorders

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending February 12, 2021.

The treatment can be used in children who do not respond well to anticholinergic medications.

The neurologist from Cleveland Clinic discussed how her study reinforced previous findings that individuals with early onset neuromyelitis optica spectrum disorders are more likely to experience severe vision loss.

While patients with relapsing-remitting MS were found to benefit more from aHSCT, patients with progressive MS still experienced stability in disability scores.

Here's what is coming soon to NeurologyLive.

Neurology News Network for the week ending February 6, 2021.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending February 5, 2021.

The annual meeting will now take place October 25–28, 2021 at the Rosen Shingle Creek in Orlando, Florida.

Treatment with low-dose protocol of rituximab is sufficient to maintain suppression of inflammatory disease activity in most patients with relapsing-remitting multiple sclerosis.

The basis of the approval for peginterferon beta-1a was from a phase 1 crossover study that showed the drug’s bioequivalence to subcutaneous injection.

Here's what is coming soon to NeurologyLive.

Neurology News Network for the week ending January 30, 2021.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending January 29, 2021.